Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:A61M1/00 AND EN_ALLTXT:(coronavirus OR coronaviruses OR coronaviridae OR coronavirinae OR orthocoronavirus OR orthocoronaviruses OR orthocoronaviridae OR orthocoronavirinae OR betacoronavirus OR betacoronaviruses OR betacoronaviridae OR betacoronavirinae OR sarbecovirus OR sarbecoviruses OR sarbecoviridae OR sarbecovirinae OR "severe acute respiratory syndrome" OR sars OR "2019 ncov" OR covid)

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.20230338520Method of treating, reducing, or alleviating a medical condition in a patient
US 26.10.2023
Int.Class A61K 39/39
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
39characterised by the immunostimulating additives, e.g. chemical adjuvants
Appl.No 18216531 Applicant Gholam A. Peyman Inventor Gholam A. Peyman

A method for producing an immunogenic composition includes growing viruses, bacteria, fungi, parasites, or tumor cells on a cell culture or other appropriate medium; harvesting the viruses, bacteria, fungi, parasites, or tumor cells; killing the viruses, bacteria, fungi, parasites, or tumor cells with one or more medications that damage the RNA and/or the DNA of the viruses, bacteria, fungi, parasites, or tumor cells; separating the dead viruses, bacteria, fungi, parasites, or tumor cells; depending on the type of organism, adding antivirals, antibacterials, antifungals, antiparasitics, and/or anti-neoplastic medications at non-toxic concentrations to the dead viruses, bacteria, fungi, parasites, or tumor cells so as to form an immunogenic composition; and administering the immunogenic composition and an adjuvant to a patient in need thereof.

2.WO/2021/243372CLOSED-LOOP ANTIMICROBIAL PHOTO-PLASMAPHERESIS
WO 02.12.2021
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
Appl.No PCT/US2021/070633 Applicant BAYLOR COLLEGE OF MEDICINE Inventor SZIGETI, Reka
The present disclosure concerns systems and methods related to the treatment, prevention, delay of onset, or reduction of severity of a microbial infection in an individual, including closed-loop plasmapheresis and extracorporeal light irradiation of the plasma of the individual. The systems and methods further relate to irradiation of the plasma of the individual with UV and/or visible light, optionally in the presence of a photosensitizer. The systems and methods further relate to light irradiation inactivation of microbial particles in the plasma taken from the individual. The systems and methods further relate to the optional filtration of microbial particles from UV light-treated plasma. The systems and methods further relate to reinfusion of the UV light-treated, optionally filtered, plasma back into the individual. The systems and methods further relate to treating, preventing, delaying onset of, or reducing in severity a viral infection, particularly a viral infection caused by a Coronaviridae family virus, at least including SARS-CoV-2. The systems and methods are further configured to reduce viral load and/or lymphocyte reinfection rate in the individual.
3.20240399042DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF
US 05.12.2024
Int.Class A61M 1/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
Appl.No 18700571 Applicant Aethlon Medical, Inc. Inventor Charles J. FISHER, Jr.

The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention directly benefits these patients by providing lectin based extracorporeal methods for binding and physically removing SARS-CoV-2 virions, or fragments thereof such as SARS-CoV-2-derived glycoproteins, non-viral COVID-19 mediating nanoparticles, such as exosomes containing SARS-CoV-2-derived glycoproteins and/or other biological molecules, including microRNAs, from the circulatory system, thereby reducing viral load in infected blood. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases.

4.WO/2023/064753DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF
WO 20.04.2023
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No PCT/US2022/077885 Applicant AETHLON MEDICAL, INC. Inventor FISHER, JR., Charles J.
The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post COVID-19 syndrome or similar post-disease sequelae symptoms of COVID-19 or similar disease. The present invention provides a lectin based extracorporeal methods for binding and physically removing SARS-CoV-2 virions, or fragments thereof such as SARS-Co V-2-derived glycoproteins, from the circulatory system, thereby reducing viral load in infected blood. The present invention also provides lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles, such as exosomes containing SARS-Co V-2-derived glycoproteins and/or other biological molecules from the circulatory system, thereby reducing the severity of the disease.
5.2022361924DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF
AU 20.04.2023
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No 2022361924 Applicant AETHLON MEDICAL, INC. Inventor CAMPION, Rosalia De Necochea
6.WO/2021/203015METHODS OF TREATING CONDITIONS
WO 07.10.2021
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
Appl.No PCT/US2021/025602 Applicant NATIONAL JEWISH HEALTH Inventor HIRSCH, Glenn, A.
The present disclosure relates to a method of treating conditions and/or diseases using blood irradiation. Conditions and diseases include cytokine storm syndrome, autoimmune diseases, and infectious diseases. The disclosure also relates to modulation of the immune system, for example by modulating leukocytes. The method involves removal of blood, exposing the removed blood to radiation, and placing the exposed blood into a patient. Radiation includes ultraviolet radiation and other types of radiation.
7.20230149617METHODS OF TREATING CONDITIONS
US 18.05.2023
Int.Class A61M 1/36
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation
Appl.No 17915907 Applicant NATIONAL JEWISH HEALTH Inventor Glenn A. HIRSCH

The present disclosure relates to a method of treating conditions and/or diseases using blood irradiation. Conditions and diseases include cytokine storm syndrome, autoimmune diseases, and infectious diseases. The disclosure also relates to modulation of the immune system, for example by modulating leukocytes. The method involves removal of blood, exposing the removed blood to radiation, and placing the exposed blood into a patient. Radiation includes ultraviolet radiation and other types of radiation.

8.3235306DEVICES AND METHODS FOR TREATING A VIRAL INFECTION AND SYMPTOMS THEREOF
CA 20.04.2023
Int.Class G01N 33/543
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
543with an insoluble carrier for immobilising immunochemicals
Appl.No 3235306 Applicant AETHLON MEDICAL, INC. Inventor FISHER, JR., CHARLES J.
The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post COVID-19 syndrome or similar post-disease sequelae symptoms of COVID-19 or similar disease. The present invention provides a lectin based extracorporeal methods for binding and physically removing SARS-CoV-2 virions, or fragments thereof such as SARS-Co V-2-derived glycoproteins, from the circulatory system, thereby reducing viral load in infected blood. The present invention also provides lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles, such as exosomes containing SARS-Co V-2-derived glycoproteins and/or other biological molecules from the circulatory system, thereby reducing the severity of the disease.
9.20230158222DEVICES AND METHODS FOR TREATING A CORONAVIRUS INFECTION AND SYMPTOMS THEREOF
US 25.05.2023
Int.Class A61M 1/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
Appl.No 17918085 Applicant Aethlon Medical, Inc. Inventor Charles J. FISHER, Jr.

The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post-COVID-19 syndrome or similar post-disease sequelae so-called “long haul” symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL-6, Troponin T, and D-dimer.

10.4136453LECTIN FOR USE IN METHODS FOR TREATING A SEQUELA OF CORONAVIRUS INFECTION
EP 22.02.2023
Int.Class A61M 1/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
1Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
34Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration, diafiltration
Appl.No 21788894 Applicant AETHLON MEDICAL INC Inventor FISHER JR CHARLES J
The devices and methods of the present invention can be used to capture and remove COVID-19 mediating nanoparticles and/or exosomes associated with COVID-19 or similar disease from the circulatory system of patients in need thereof, including those with post- COVID- 19 syndrome or similar post-disease sequelae so-called "long haul" symptoms of COVID-19 or similar disease. The present invention benefits patients by providing lectin based extracorporeal methods for binding and physically removing SA RS-C7oV-2 virions, or fragments thereof, from the circulatory system. Also provided are lectin based extracorporeal methods of binding and physically removing non-viral COVID-19 mediating nanoparticles. Also disclosed herein are devices and methods for reducing the levels of biomarkers and markers of morbidity/mortality of diseases such as COVID-19 and similar diseases, including cytokines, such as IL- 6, Troponin T, and D- dimer.